-
Je něco špatně v tomto záznamu ?
Cerebral Microbleeds and Amyloid Pathology Estimates From the Amyloid Biomarker Study
JE. Oomens, V. van Gils, SJB. Vos, WM. Freeze, NN. Maserejian, G. Curiale, C. Gillis, M. Boada, WM. van der Flier, J. Hort, SC. Johnson, A. Lleó, IH. Ramakers, KM. Rodrigue, P. Sánchez-Juan, M. Sarazin, N. Scarmeas, H. Zetterberg, D. Alcolea, F....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
Grantová podpora
R01 AG027161
NIA NIH HHS - United States
NLK
Directory of Open Access Journals
od 2018
ProQuest Central
od 2018-01-01
Health & Medicine (ProQuest)
od 2018-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2018
- MeSH
- Alzheimerova nemoc * epidemiologie genetika MeSH
- amyloidní beta-protein * metabolismus mozkomíšní mok MeSH
- amyloidní plaky patologie MeSH
- apolipoprotein E4 genetika MeSH
- biologické markery * mozkomíšní mok MeSH
- cerebrální krvácení * epidemiologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- magnetická rezonanční tomografie metody MeSH
- pozitronová emisní tomografie MeSH
- průřezové studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
IMPORTANCE: Baseline cerebral microbleeds (CMBs) and APOE ε4 allele copy number are important risk factors for amyloid-related imaging abnormalities in patients with Alzheimer disease (AD) receiving therapies to lower amyloid-β plaque levels. OBJECTIVE: To provide prevalence estimates of any, no more than 4, or fewer than 2 CMBs in association with amyloid status, APOE ε4 copy number, and age. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used data included in the Amyloid Biomarker Study data pooling initiative (January 1, 2012, to the present [data collection is ongoing]). Data from 15 research and memory clinic studies were pooled and harmonized. Participants included individuals for whom data on age, cognitive status, amyloid status, and presence of CMBs were available. Data were analyzed from October 22, 2023, to April 26, 2024. MAIN OUTCOMES AND MEASURES: The main outcomes were age, cognitive status, amyloid status and presence, location, and number of CMBs. Presence of amyloid pathology was determined based on 42 amino acid-long form of amyloid-β peptide (Aβ42) levels in cerebrospinal fluid or on amyloid-positron emission tomography. Presence and, in a subset, location (lobar vs deep) and number of CMBs were determined on magnetic resonance imaging (locally with visual rating). RESULTS: Among 4080 participants included in the analysis, the mean (SD) age was 66.5 (8.9) years, and 2241 (54.9%) were female. A total of 2973 participants had no cognitive impairment (cognitive unimpairment [CU]), and 1107 had mild cognitive impairment (MCI) or AD dementia (ADD). One thousand five hundred and thirteen participants (37.1%) had amyloid pathology, 1368 of 3599 (38.0%) with data available were APOE ε4 carriers, and 648 (15.9%) had CMBs. In the CU group, amyloid pathology and APOE ε4 copy number were not associated with presence of any, no more than 4, or fewer than 2 CMBs but were associated with increased odds of lobar CMBs (odds ratio [OR] for amyloid, 1.42 [95% CI, 1.20-1.69], P < .001; OR for 2 vs 0 alleles, 1.81 [95% CI, 1.19-2.74], P = .006; OR for 1 vs 0 alleles, 1.10 [95% CI, 0.83-1.46], P = .49; and OR for 2 vs 1 allele, 1.64 [95% CI, 0.90-2.97], P = .11; overall P = .02). In the MCI-ADD group, amyloid pathology was associated with presence of any CMBs (OR, 1.51 [95% CI, 1.17-1.96], P = .002), no more than 4 CMBs (OR, 1.44 [95% CI, 1.18-1.82], P = .002), and fewer than 2 CMBs (OR 1.34 [95% CI, 1.03-1.74], P = .03) but not lobar CMBs. APOE ε4 copy number was associated with presence of any (OR for 2 vs 0 alleles, 1.72 [95% CI, 0.88-3.35], P = .11; OR for 1 vs 0 alleles, 0.78 [95% CI, 0.59-1.04], P = .09; and OR for 2 vs 1 allele, 2.20 [95% CI, 1.32-3.67], P = .002; overall P < .001) and no more than 4 CMBs (OR for 2 vs 0 alleles, 1.31 [95% CI, 0.64-2.68], P = .45; OR for 1 vs 0 alleles, 0.75 [95% CI, 0.54-1.04], P = .08; and OR for 2 vs 1 allele, 1.76 [95% CI, 0.97-3.19], P = .06; overall P = .03) but not with fewer than 2 or lobar CMBs. Prevalence estimates of CMBs ranged from 6% at 50 years of age in a non-APOE ε4 allele carrier with no amyloid pathology and no cognitive impairment to 52% at 90 years of age in an APOE ε4 homozygote carrier with amyloid pathology and cognitive impairment. CONCLUSIONS AND RELEVANCE: In this cross-sectional study of 4080 participants, prevalence estimates of CMBs were associated with amyloid status, APOE ε4 copy number, and age. CMB prevalence estimates may help inform safety evaluations for antiamyloid clinical trials.
Ace Alzheimer Center Barcelona Universitat Internacional de Catalunya Barcelona Spain
Amsterdam Neuroscience Brain Imaging Amsterdam the Netherlands
Banner Alzheimer's Institute Phoenix Arizona
Center for Vital Longevity School of Behavioral and Brain Sciences University of Texas at Dallas
Cerebriu A S Copenhagen Denmark
Clinical Neurochemistry Laboratory Sahlgrenska University Hospital Mölndal Sweden
Department of Diagnostic Radiology Copenhagen University Hospital Rigshospitalet Copenhagen Denmark
Department of Medicine and Psychiatry University of Cantabria Santander Santander Spain
Department of Neurobiology Care Sciences and Society Karolinska Institutet Stockholm Sweden
Department of Neurology Columbia University New York New York
Department of Neurology Marqués de Valdecilla University Hospital and IDIVAL Santander Spain
Department of Nuclear Medicine Marqués de Valdecilla University Hospital and IDIVAL Santander Spain
Department of Radiology Leiden University Medical Center Leiden the Netherlands
Hong Kong Center for Neurodegenerative Diseases Hong Kong China
Memory Unit Neurology Department Hospital de la Santa Creu i Sant Pau Barcelona Spain
Research and Development Biogen Inc Cambridge Massachusetts
UK Dementia Research Institute London United Kingdom
Wisconsin Alzheimer's Institute School of Medicine and Public Health University of Wisconsin Madison
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25010345
- 003
- CZ-PrNML
- 005
- 20250429135509.0
- 007
- ta
- 008
- 250415s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1001/jamanetworkopen.2024.55571 $2 doi
- 035 __
- $a (PubMed)39841474
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Oomens, Julie E $u Alzheimer Center Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands
- 245 10
- $a Cerebral Microbleeds and Amyloid Pathology Estimates From the Amyloid Biomarker Study / $c JE. Oomens, V. van Gils, SJB. Vos, WM. Freeze, NN. Maserejian, G. Curiale, C. Gillis, M. Boada, WM. van der Flier, J. Hort, SC. Johnson, A. Lleó, IH. Ramakers, KM. Rodrigue, P. Sánchez-Juan, M. Sarazin, N. Scarmeas, H. Zetterberg, D. Alcolea, F. Barkhof, K. Blennow, M. Bottlaender, A. den Braber, J. Cerman, M. Drake-Perez, J. Fortea, R. Handels, S. Ingala, JF. Jiménez-Bonilla, S. Karavasilis, J. Lagarde, N. Legdeur, L. Lorenzini, M. Marquié, JEF. Moonen, P. Olivieri, A. Orellana, R. Ossenkoppele, LA. Rivera-Rivera, E. Rodríguez-Rodriguez, A. Ruiz Laza, CE. Teunissen, BM. Tijms, G. Velonakis, FRJ. Verhey, PJ. Visser, WJ. Jansen, European Prevention of Alzheimer’s Dementia (EPAD) Consortium, Fundació ACE Healthy Brain Initiative (FACEHBI) Study Group, BIOFACE Study Group
- 520 9_
- $a IMPORTANCE: Baseline cerebral microbleeds (CMBs) and APOE ε4 allele copy number are important risk factors for amyloid-related imaging abnormalities in patients with Alzheimer disease (AD) receiving therapies to lower amyloid-β plaque levels. OBJECTIVE: To provide prevalence estimates of any, no more than 4, or fewer than 2 CMBs in association with amyloid status, APOE ε4 copy number, and age. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used data included in the Amyloid Biomarker Study data pooling initiative (January 1, 2012, to the present [data collection is ongoing]). Data from 15 research and memory clinic studies were pooled and harmonized. Participants included individuals for whom data on age, cognitive status, amyloid status, and presence of CMBs were available. Data were analyzed from October 22, 2023, to April 26, 2024. MAIN OUTCOMES AND MEASURES: The main outcomes were age, cognitive status, amyloid status and presence, location, and number of CMBs. Presence of amyloid pathology was determined based on 42 amino acid-long form of amyloid-β peptide (Aβ42) levels in cerebrospinal fluid or on amyloid-positron emission tomography. Presence and, in a subset, location (lobar vs deep) and number of CMBs were determined on magnetic resonance imaging (locally with visual rating). RESULTS: Among 4080 participants included in the analysis, the mean (SD) age was 66.5 (8.9) years, and 2241 (54.9%) were female. A total of 2973 participants had no cognitive impairment (cognitive unimpairment [CU]), and 1107 had mild cognitive impairment (MCI) or AD dementia (ADD). One thousand five hundred and thirteen participants (37.1%) had amyloid pathology, 1368 of 3599 (38.0%) with data available were APOE ε4 carriers, and 648 (15.9%) had CMBs. In the CU group, amyloid pathology and APOE ε4 copy number were not associated with presence of any, no more than 4, or fewer than 2 CMBs but were associated with increased odds of lobar CMBs (odds ratio [OR] for amyloid, 1.42 [95% CI, 1.20-1.69], P < .001; OR for 2 vs 0 alleles, 1.81 [95% CI, 1.19-2.74], P = .006; OR for 1 vs 0 alleles, 1.10 [95% CI, 0.83-1.46], P = .49; and OR for 2 vs 1 allele, 1.64 [95% CI, 0.90-2.97], P = .11; overall P = .02). In the MCI-ADD group, amyloid pathology was associated with presence of any CMBs (OR, 1.51 [95% CI, 1.17-1.96], P = .002), no more than 4 CMBs (OR, 1.44 [95% CI, 1.18-1.82], P = .002), and fewer than 2 CMBs (OR 1.34 [95% CI, 1.03-1.74], P = .03) but not lobar CMBs. APOE ε4 copy number was associated with presence of any (OR for 2 vs 0 alleles, 1.72 [95% CI, 0.88-3.35], P = .11; OR for 1 vs 0 alleles, 0.78 [95% CI, 0.59-1.04], P = .09; and OR for 2 vs 1 allele, 2.20 [95% CI, 1.32-3.67], P = .002; overall P < .001) and no more than 4 CMBs (OR for 2 vs 0 alleles, 1.31 [95% CI, 0.64-2.68], P = .45; OR for 1 vs 0 alleles, 0.75 [95% CI, 0.54-1.04], P = .08; and OR for 2 vs 1 allele, 1.76 [95% CI, 0.97-3.19], P = .06; overall P = .03) but not with fewer than 2 or lobar CMBs. Prevalence estimates of CMBs ranged from 6% at 50 years of age in a non-APOE ε4 allele carrier with no amyloid pathology and no cognitive impairment to 52% at 90 years of age in an APOE ε4 homozygote carrier with amyloid pathology and cognitive impairment. CONCLUSIONS AND RELEVANCE: In this cross-sectional study of 4080 participants, prevalence estimates of CMBs were associated with amyloid status, APOE ε4 copy number, and age. CMB prevalence estimates may help inform safety evaluations for antiamyloid clinical trials.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a cerebrální krvácení $x epidemiologie $7 D002543
- 650 _2
- $a průřezové studie $7 D003430
- 650 12
- $a Alzheimerova nemoc $x epidemiologie $x genetika $7 D000544
- 650 12
- $a amyloidní beta-protein $x metabolismus $x mozkomíšní mok $7 D016229
- 650 12
- $a biologické markery $x mozkomíšní mok $7 D015415
- 650 _2
- $a apolipoprotein E4 $x genetika $7 D053327
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a pozitronová emisní tomografie $7 D049268
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a amyloidní plaky $x patologie $7 D058225
- 650 _2
- $a magnetická rezonanční tomografie $x metody $7 D008279
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a van Gils, Veerle $u Alzheimer Center Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands
- 700 1_
- $a Vos, Stephanie J B $u Alzheimer Center Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands
- 700 1_
- $a Freeze, Whitney M $u Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
- 700 1_
- $a Maserejian, Nancy N $u Research and Development, Biogen Inc, Cambridge, Massachusetts
- 700 1_
- $a Curiale, Gioacchino $u Research and Development, Biogen Inc, Cambridge, Massachusetts
- 700 1_
- $a Gillis, Cai $u Research and Development, Biogen Inc, Cambridge, Massachusetts
- 700 1_
- $a Boada, Mercè $u Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain $u Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain
- 700 1_
- $a van der Flier, Wiesje M $u Department of Neurology, Alzheimer Centre Amsterdam, Amsterdam Neuroscience, Amsterdam UMC Locatie VUmc, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands $u Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam UMC Locatie VUmc, Amsterdam, the Netherlands
- 700 1_
- $a Hort, Jakub $u Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Johnson, Sterling C $u Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison $u Wisconsin Alzheimer's Institute, School of Medicine and Public Health, University of Wisconsin-Madison
- 700 1_
- $a Lleó, Alberto $u Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain $u Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- 700 1_
- $a Ramakers, Inez H $u Alzheimer Center Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands
- 700 1_
- $a Rodrigue, Karen M $u Center for Vital Longevity, School of Behavioral and Brain Sciences, University of Texas at Dallas
- 700 1_
- $a Sánchez-Juan, Pascual $u Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain $u Alzheimer's Centre Reina Sofia, Research Centre on Neurological Diseases (CIBERNED), Carlos III Health Institute, Madrid, Spain
- 700 1_
- $a Sarazin, Marie $u Department of Neurology of Memory and Language, Groupe Hospitalier Universitaire Paris Psychiatry and Neurosciences, Hôpital Sainte Anne, Paris, France $u Paris-Saclay University, BioMaps, French National Institute of Health and Medical Research, Alternative Energies and Atomic Energy Commission (CEA), Service Hospitalier Frederic Joliot, Orsay, France
- 700 1_
- $a Scarmeas, Nikolaos $u First Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece $u Department of Neurology, Columbia University, New York, New York
- 700 1_
- $a Zetterberg, Henrik $u Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison $u Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden $u Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden $u Department of Neurodegenerative Disease, University College London (UCL) Queen Square Institute of Neurology, London, United Kingdom $u UK Dementia Research Institute, London, United Kingdom $u Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China
- 700 1_
- $a Alcolea, Daniel $u Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain $u Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- 700 1_
- $a Barkhof, Frederik $u Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam Locatie VUmc, Amsterdam, the Netherlands $u Queen Square Institute of Neurology and Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, UCL, London, United Kingdom
- 700 1_
- $a Blennow, Kaj $u Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
- 700 1_
- $a Bottlaender, Michel $u Paris-Saclay University, BioMaps, French National Institute of Health and Medical Research, Alternative Energies and Atomic Energy Commission (CEA), Service Hospitalier Frederic Joliot, Orsay, France $u Paris-Saclay University, Translational and Applicative Neuroimaging Research Unit, Neurospin, CEA, Gif-sur-Yvette, France
- 700 1_
- $a den Braber, Anouk $u Department of Neurology, Alzheimer Centre Amsterdam, Amsterdam Neuroscience, Amsterdam UMC Locatie VUmc, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
- 700 1_
- $a Cerman, Jirí $u Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Drake-Perez, Marta $u Department of Radiology, Marqués de Valdecilla University Hospital and Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain
- 700 1_
- $a Fortea, Juan $u Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain $u Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- 700 1_
- $a Handels, Ron $u Alzheimer Center Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands
- 700 1_
- $a Ingala, Silvia $u Department of Diagnostic Radiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark $u Cerebriu A/S, Copenhagen, Denmark
- 700 1_
- $a Jiménez-Bonilla, Julio F $u Department of Nuclear Medicine, Marqués de Valdecilla University Hospital and IDIVAL, Santander, Spain
- 700 1_
- $a Karavasilis, Stratos $u Department of Neuroradiology, Aiginition Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece
- 700 1_
- $a Lagarde, Julien $u Department of Neurology of Memory and Language, Groupe Hospitalier Universitaire Paris Psychiatry and Neurosciences, Hôpital Sainte Anne, Paris, France $u Paris-Saclay University, BioMaps, French National Institute of Health and Medical Research, Alternative Energies and Atomic Energy Commission (CEA), Service Hospitalier Frederic Joliot, Orsay, France
- 700 1_
- $a Legdeur, Nienke $u Department of Neurology, Alzheimer Centre Amsterdam, Amsterdam Neuroscience, Amsterdam UMC Locatie VUmc, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
- 700 1_
- $a Lorenzini, Luigi $u Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam Locatie VUmc, Amsterdam, the Netherlands $u Amsterdam Neuroscience, Brain Imaging, Amsterdam, the Netherlands
- 700 1_
- $a Marquié, Marta $u Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain $u Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain
- 700 1_
- $a Moonen, Justine E F $u Department of Neurology, Alzheimer Centre Amsterdam, Amsterdam Neuroscience, Amsterdam UMC Locatie VUmc, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
- 700 1_
- $a Olivieri, Pauline $u Department of Neurology of Memory and Language, Groupe Hospitalier Universitaire Paris Psychiatry and Neurosciences, Hôpital Sainte Anne, Paris, France
- 700 1_
- $a Orellana, Adelina $u Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain $u Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain
- 700 1_
- $a Ossenkoppele, Rik $u Department of Neurology, Alzheimer Centre Amsterdam, Amsterdam Neuroscience, Amsterdam UMC Locatie VUmc, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
- 700 1_
- $a Rivera-Rivera, Leonardo A $u Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison $u Wisconsin Alzheimer's Institute, School of Medicine and Public Health, University of Wisconsin-Madison
- 700 1_
- $a Rodríguez-Rodriguez, Eloy $u Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain $u Department of Neurology, Marqués de Valdecilla University Hospital and IDIVAL, Santander, Spain $u Department of Medicine and Psychiatry, University of Cantabria, Santander, Santander, Spain
- 700 1_
- $a Ruiz Laza, Agustín $u Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain $u Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain
- 700 1_
- $a Teunissen, Charlotte E $u Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Amsterdam UMC Locatie VUmc, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
- 700 1_
- $a Tijms, Betty M $u Department of Neurology, Alzheimer Centre Amsterdam, Amsterdam Neuroscience, Amsterdam UMC Locatie VUmc, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
- 700 1_
- $a Velonakis, Giorgos $u Department of Neuroradiology, Aiginition Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece
- 700 1_
- $a Verhey, Frans R J $u Alzheimer Center Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands
- 700 1_
- $a Visser, Pieter Jelle $u Alzheimer Center Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands $u Department of Neurology, Alzheimer Centre Amsterdam, Amsterdam Neuroscience, Amsterdam UMC Locatie VUmc, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands $u Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Jansen, Willemijn J $u Alzheimer Center Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands $u Banner Alzheimer's Institute, Phoenix, Arizona
- 710 2_
- $a European Prevention of Alzheimer’s Dementia (EPAD) Consortium
- 710 2_
- $a Fundació ACE Healthy Brain Initiative (FACEHBI) Study Group
- 710 2_
- $a BIOFACE Study Group
- 773 0_
- $w MED00205674 $t JAMA network open $x 2574-3805 $g Roč. 8, č. 1 (2025), s. e2455571
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39841474 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429135504 $b ABA008
- 999 __
- $a ok $b bmc $g 2311603 $s 1247426
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 8 $c 1 $d e2455571 $e 20250102 $i 2574-3805 $m JAMA network open $n JAMA Netw Open $x MED00205674
- GRA __
- $a R01 AG027161 $p NIA NIH HHS $2 United States
- LZP __
- $a Pubmed-20250415
